Nystatin nanosizing enhances in vitro and in vivo antifungal activity against Candida albicans

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2099-2105

  Melkoumov, Alexandre ^a   Goupil, Mathieu ^a   Louhichi, Fatiha ^b   Raymond, Martine ^b   De Repentigny, Louis ^a   Leclair, Grégoire ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Drug delivery; Nanosuspensions; Oral candidiasis

Indexed keywords

AGAR; CORTISONE ACETATE; L SELECTIN; NYSTATIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANDIDA ALBICANS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DBA 2 MOUSE; DRUG FORMULATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LASER DIFFRACTION; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; THRUSH; TREATMENT DURATION;

DRUG DELIVERY; NANOSUSPENSIONS; ORAL CANDIDIASIS;

ANIMAL STRUCTURES; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED DBA; MICROBIAL SENSITIVITY TESTS; MOUTH; NANOPARTICLES; NYSTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84882637134     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt137     Document Type: Article

References (43)

1. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002; 78: 455-9.
2. Gonzalez Gravina H, Gonzalez de Moran E, Zambrano O et al. Oral candidiasis in children and adolescents with cancer. Identification of Candida spp. Med Oral Patol Oral Cir Bucal 2007; 12: E419-23.
3. de Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004; 17: 729-59.
4. Spellberg B. Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge. PLoS Pathog 2008; 4: e38.
5. Lopez-Martinez R. Candidosis, a new challenge. Clin Dermatol 2010; 28: 178-84.
6. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20: 485-506.
7. Carrillo-Munoz AJ, Quindos G, Tur C et al. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 44: 397-401.
8. Kovacic P, Cooksy A. Novel, unifying mechanism for amphotericin B and other polyene drugs: electron affinity, radicals, electron transfer, autoxidation, toxicity, and antifungal action. Med Chem Commun 2012; 3: 274-80.
9. Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front Microbiol 2012; doi:10.3389/fmicb.2012.00286.
10. Ratiopharm. Product Monograph (ratio-Nystatin). 2001; G50-G5.
11. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis.2009 update by the Infectious Diseases Society of America Clin Infect Dis 2009; 48: 503-35.
12. Pons V, Greenspan D, Lozada-Nur F et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24: 1204-7.
13. Depont F, Vargas F, Dutronc H et al. Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf 2007; 16: 1227-33.
14. Lee JW, Seibel NL, Amantea M et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987-93.
15. Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15-25.
16. Martinez M, Lopez-Ribot JL, Kirkpatrick WR et al. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 2002; 49: 515-24.
17. Kayser O, Olbrich C, Yardley V et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254: 73-5.
18. Lemke A, Kiderlen AF, Petri B et al. Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas. Nanomedicine 2010; 6: 597-603.
19. Italia JL, Sharp A, Carter KC et al. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome(R) or Fungizone. PLoS One 2011; 6: e25744.
20. Xu N, Gu J, Zhu Y et al. Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice. Int J Nanomedicine 2011; 6: 905-13.
21. Bin Ahmad M, Lim JJ, Shameli K et al. Antibacterial activity of silver bionanocomposites synthesized by chemical reduction route. Chem Cent J 2012; 6: 101.
22. Dal Lago V, Franca de Oliveira L, de Almeida Goncalves K et al. Size-selective silver nanoparticles: future of biomedical devices with enhanced bactericidal properties. J Mater Chem 2011; 21: 12267-73.
23. Morones JR, Elechiguerra JL, Camacho A et al. The bactericidal effect of silver nanoparticles. Nanotechnology 2005; 16: 2346-53.
24. Flynn PM, Cunningham CK, Kerkering Tet al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127: 322-8.
25. Llabot JM, Manzo RH, Allemandi DA. Novel mucoadhesive extended release tablets for treatment of oral candidosis: 'in vivo' evaluation of the biopharmaceutical performance. J Pharm Sci 2009; 98: 1871-6.
26. Llabot JM, Palma SD, Manzo RH et al. Design of novel antifungal mucoadhesive films. Part II. Formulation and in vitro biopharmaceutical evaluation. Int J Pharm 2007; 336: 263-8.
27. Campos FF, Calpena Campmany AC, Delgado GR et al. Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: Ultrastructural effects and release studies. J Pharm Sci 2012; 101: 3739-52.
28. Gunderson SM, Hoffman H, Ernst EJ et al. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect. Antimicrob Agents Chemother 2000; 44: 2887-90.
29. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179-82.
30. Jones T, Federspiel NA, Chibana H et al. The diploid genome sequence of Candida albicans. Proc Natl Acad Sci USA 2004; 101: 7329-34.
31. Lacasse M, Fortier C, Trudel L et al. Experimental oral candidosis in the mouse: microbiologic and histologic aspects. J Oral Pathol Med 1990; 19: 136-41.
32. Groll AH, Mickiene D, Werner K et al. High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies. J Chromatogr B Biomed Sci Appl 1999; 735: 51-62.
33. Solis NV, Filler SG. Mouse model of oropharyngeal candidiasis. Nat Protoc 2012; 7: 637-42.
34. de Repentigny L, Lewandowski D, Aumont F et al. Oral mucosal cell response to Candida albicans in transgenic mice expressing HIV-1. Methods Mol Biol 2009; 470: 359-68.
35. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008; 36: 43-8.
36. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
37. National Committee for Clinical Laboratory Standards. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts-Second Edition: Approved Standard M44-A2. NCCLS, Wayne, PA, USA, 2004.
38. Kamai Y, Kubota M, Kamai Y et al. New model of oropharyngeal candidiasis in mice. Antimicrob Agents Chemother 2001; 45: 3195-7.
39. Matsubara VH, Silva EG, Paula CR et al. Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2). Oral Dis 2012; 18: 260-4.
40. Ashman RB, Papadimitriou JM, Fulurija A et al. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb Pathog 2003; 34: 103-13.
41. Chakir J, Cote L, Coulombe C et al. Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 (H-2d) mice. Oral Microbiol Immunol 1994; 9: 88-94.
42. Radovanovic I, Mullick A, Gros P. Genetic control of susceptibility to infection with Candida albicans in mice. PLoS One 2011; 6: e18957.
43. de Repentigny L, Aumont F, Ripeau JS et al. Mucosal candidiasis in transgenic mice expressing human immunodeficiency virus type 1. J Infect Dis 2002; 185: 1103-14.